Kairos Pharma's ENV-105 combination extends median progression-free survival to 17.7 months in Phase 2 prostate cancer trial
PUBT · 1d ago
Share
Listen to the news
- Kairos Pharma will present interim ENV-105 efficacy results today at the 11th International Conference on Cancer Research & Drug Development in Houston.
- Phase 2 results showed ENV-105 with apalutamide significantly delayed disease progression versus apalutamide alone in metastatic castration-resistant prostate cancer.
- The trial will now focus on first-line therapy following enzalutamide, expanding enrollment to assess treatment resistance.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611031145BIZWIRE_USPR_____20261103_BW858849) on November 03, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending